GLP-1 Dose Titration & Weight Loss Tracker
Track Semaglutide (Wegovy/Ozempic) and Tirzepatide (Zepbound/Mounjaro) 4-week titration schedules, trial loss benchmarks, and lean muscle preservation protein goals.
Calculated Results
Frequently Asked Questions
Why is a 4-week dose escalation schedule mandatory for GLP-1 medications?
GLP-1 receptor agonists delay gastric emptying and signal brain satiety centers. Escalating the dose gradually every 4 weeks allows your gastrointestinal tract to adapt, drastically reducing nausea, vomiting, and acid reflux.
What is the official titration schedule for Semaglutide (Wegovy)?
Weeks 1–4: 0.25 mg; Weeks 5–8: 0.5 mg; Weeks 9–12: 1.0 mg; Weeks 13–16: 1.7 mg; Weeks 17+: 2.4 mg full therapeutic maintenance dose.
What is the difference in clinical trial weight loss between Semaglutide and Tirzepatide?
In the landmark STEP-1 clinical trial, Semaglutide 2.4mg produced an average of 14.9% total body weight loss at 68 weeks. In the SURMOUNT-1 trial, dual GIP/GLP-1 Tirzepatide 15mg achieved up to 20.9% average body weight loss at 72 weeks.
Why is resistance training and high protein vital while on GLP-1 drugs?
Up to 25% to 40% of rapid weight lost on GLP-1 therapy can come from lean skeletal muscle mass if protein is inadequate. Consuming 0.8g to 1.0g of protein per pound of target bodyweight combined with resistance training preserves lean mass and resting metabolic rate.